CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Emergent Biosolutions Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Emergent Biosolutions Inc
300 Professional Dr
Phone: (240) 631-3200p:240 631-3200 GAITHERSBURG, MD  20879  United States Ticker: EBSEBS
Business Summary
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-YesYes--

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board ZsoltHarsanyi 80 4/1/2022 8/1/2004
President, Chief Executive Officer, Director Joseph C.Papa 68 2/21/2024 2/21/2024
Chief Financial Officer, Executive Vice President, Treasurer Richard S.Lindahl 60 8/9/2023 3/26/2018
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ADAPT Pharma Operations Limited 45 Fitzwilliam Square Dublin Ireland
Twinstrand Therapeutics Inc. 8081 Lougheed Highway Burnaby BC Canada
PAXVAX BERNA OBERRIEDSTRASSE 68 THAuRISHAUS BE
5 additional Subsidiary records available in full report.

Business Names
Business Name
2396638 Ontario Inc.
ACAM2000
Baltimore LLC Emergent Product Development
31 additional Business Names available in full report.

General Information
Number of Employees: 1,600 (As of 12/31/2023)
Outstanding Shares: 54,184,186 (As of 10/30/2024)
Shareholders: 19
Stock Exchange: NYSE
Federal Tax Id: 141902018
Fax Number: (240) 631-3203


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024